KR20250023471A - Cd73 항체 칵테일 요법 - Google Patents
Cd73 항체 칵테일 요법 Download PDFInfo
- Publication number
- KR20250023471A KR20250023471A KR1020257000422A KR20257000422A KR20250023471A KR 20250023471 A KR20250023471 A KR 20250023471A KR 1020257000422 A KR1020257000422 A KR 1020257000422A KR 20257000422 A KR20257000422 A KR 20257000422A KR 20250023471 A KR20250023471 A KR 20250023471A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen binding
- binding protein
- pharmaceutical composition
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210639331.4 | 2022-06-08 | ||
| CN202210639331 | 2022-06-08 | ||
| PCT/CN2023/098753 WO2023236971A1 (zh) | 2022-06-08 | 2023-06-07 | Cd73抗体鸡尾酒疗法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250023471A true KR20250023471A (ko) | 2025-02-18 |
Family
ID=89117604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257000422A Pending KR20250023471A (ko) | 2022-06-08 | 2023-06-07 | Cd73 항체 칵테일 요법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260217849A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4538289A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025521231A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250023471A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119403832A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3258260A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202405018A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023236971A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| EP4058150A2 (en) * | 2019-11-15 | 2022-09-21 | Genzyme Corporation | Biparatopic cd73 antibodies |
| JP2023546743A (ja) * | 2020-10-23 | 2023-11-07 | 中山康方生物医▲藥▼有限公司 | 抗cd73抗体及びその使用 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Cd73的抗原結合蛋白及其應用 |
| US20240067747A1 (en) * | 2021-01-13 | 2024-02-29 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Cd73-binding protein and use thereof |
-
2023
- 2023-06-07 WO PCT/CN2023/098753 patent/WO2023236971A1/zh not_active Ceased
- 2023-06-07 EP EP23819136.5A patent/EP4538289A4/en active Pending
- 2023-06-07 US US18/872,421 patent/US20260217849A1/en active Pending
- 2023-06-07 KR KR1020257000422A patent/KR20250023471A/ko active Pending
- 2023-06-07 CA CA3258260A patent/CA3258260A1/en active Pending
- 2023-06-07 TW TW112121274A patent/TW202405018A/zh unknown
- 2023-06-07 CN CN202380045319.3A patent/CN119403832A/zh active Pending
- 2023-06-07 JP JP2024572421A patent/JP2025521231A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025521231A (ja) | 2025-07-08 |
| US20260217849A1 (en) | 2026-07-30 |
| CA3258260A1 (en) | 2025-03-18 |
| TW202405018A (zh) | 2024-02-01 |
| WO2023236971A1 (zh) | 2023-12-14 |
| EP4538289A1 (en) | 2025-04-16 |
| EP4538289A4 (en) | 2026-06-17 |
| CN119403832A (zh) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514693A (ja) | Muc18に特異的な抗体 | |
| JP6900051B2 (ja) | Claudin 5抗体、及びその抗体を含有する医薬 | |
| CN118591564A (zh) | 一种双特异性抗原结合分子及其应用 | |
| JP2022514786A (ja) | Muc18に特異的な抗体 | |
| US9587034B2 (en) | Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains | |
| CN119487079A (zh) | 一种pvrig/tigit双特异性抗体药物组合物及其用途 | |
| US11873333B2 (en) | Compositions and methods comprising SFRP2 antagonists | |
| KR20250016156A (ko) | 재조합 항-인간 cldn18.2 단일클론 항체-mma 접합체의 약학적 조성물 | |
| CN116323657B (zh) | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 | |
| WO2022068894A1 (zh) | 同时靶向pd-l1和vegf的双功能分子及其医药用途 | |
| CN112839961B (zh) | 一种cd40抗体药物组合物及其用途 | |
| US20240392037A1 (en) | Molecules that bind to neutrophil elastase polypeptides | |
| EP4538289A1 (en) | Cd73 antibody cocktail therapy | |
| CN118576543A (zh) | 一种结合人CD3/IL13Rα的双特异性抗体制剂及其应用 | |
| EA053234B1 (ru) | Терапия коктейлем антител против cd73 | |
| TW202313105A (zh) | 與貝伐單抗的抗葉酸受體結合物組合療法 | |
| CN117545504A (zh) | 抗人血清白蛋白的抗原结合蛋白 | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| US20240124576A1 (en) | Preparation of siglec-15 binding protein and use thereof | |
| US20240092914A1 (en) | Depletion and inhibition of plasmacytoid dendritic cells | |
| EP4501313A1 (en) | Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof | |
| TW202528350A (zh) | 抗dr5和ceacam5的雙特異性抗體及其用途 | |
| TW202409092A (zh) | Cd39/cd73雙特異性抗原結合蛋白及其用途 | |
| CN121154535A (zh) | 一种多特异性抗体药物组合物、其制备方法及其用途 | |
| KR20250021320A (ko) | 항-cd228 항체 및 이의 약물 접합체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |